Unlock Strategic Intelligence with Fundz

Access exclusive insights on funding rounds, strategic shifts with FundzWatch™, Family Offices, and more — faster than your competitors.

Petdx Raises $62 Million In Series B Financing To Scale Adoption Of Its Canine Multi-Cancer Early Detection Blood Test, Oncok9

12/09/21, 9:02 AM

Location

san diego

Money raised

$62 million

Industry

biotechnology

financial services

health care

community and lifestyle

Round Type

series b

PetDx® today announced the completion of its Series B financing with over $62 million in new capital raised, which is one of the biggest Series B rounds for a pet startup; bringing the company's total funding to date to $72 million. The financing was led by Longview Asset Management with participation by Declaration Partners, Torch Capital, Aperture Venture Partners, Valor Equity Partners, Friedman Bioventure, K4 Family Investments, and Labcorp (NYSE:LH). The company's $10M Series A financing in August 2020 was led by Friedman Bioventure with participation from Petco (Nasdaq:WOOF) and an undisclosed leading pet healthcare company.

🔒 Strategic shifts and deeper insights are available for this company. Unlock full access to view hidden updates, executive moves, and more.

Company Info

Company

Pet Dx

Location

san diego, california, united states

Additional Info

PetDx® – The Liquid Biopsy Company for Pets is a San Diego-based molecular diagnostics company dedicated to unleashing the power of genomics to improve pet health. The company's flagship product, OncoK9®, enables veterinarians to detect cancer in dogs with a simple blood draw. As a first-in-class multi-cancer early detection (MCED) test, OncoK9 employs cutting-edge genomic analysis that leverages next-generation sequencing (NGS) technology and proprietary bioinformatics algorithms, empowering veterinarians to provide superior care to canine patients. To learn more, visit www.petdx.com.

Company news

Thu, 13 Jan 2022 08:00:00 GMT

PetDx and IDEXX partner for expanded access to novel cancer test for dogs - DVM360

Thu, 20 May 2021 07:00:00 GMT

PetDx launches OncoK9™, a pioneering blood-based multi-cancer early detection (MCED) test for dogs - PR Newswire

Wed, 01 Feb 2023 08:00:00 GMT

Size, Sex and Breed May Predict Dogs’ Cancer Diagnosis - Scientific American

Wed, 02 Jun 2021 07:00:00 GMT

PetDx launches new multi-cancer screening test for dogs - DVM360

Thu, 09 Dec 2021 08:00:00 GMT

PetDx Raises $62 Million in Series B Financing to Scale Adoption of its Canine Multi-Cancer Early Detection Blood Test, OncoK9 - PR Newswire

Thu, 13 Jan 2022 08:00:00 GMT

PetDx and IDEXX Expand Access to OncoK9, the Cancer Liquid Biopsy Test for Dogs - PR Newswire

Tue, 24 Jan 2023 08:00:00 GMT

PetDx Appoints Alejandro Bernal as its New President and Chief Executive Officer - PR Newswire

Track Every New Funding Round — Before Anyone Else

This is just a small preview. Unlock access to thousands more filtered results — updated in real-time by stage, region, investor & more.

Trusted by sales, BD, and investment teams at Oracle, HubSpot, Affinity, and more.

Trends

	Raised	Growth The data in the raised column shows reported funding for this location/industry over last 90 days. The data in the growth column indicates the % increase or decrease of the last 90 days vs. the previous 90 days. Please note: one or more large fundings, especially for a location/industry that doesn't historically receive much funding, can have a significant impact on the increase or decrease percentage.
san diego	$450.3 M	-38.5%
biotechnology	$9.4 B	-17.2%
health care	$8 B	-30.5%